GlaxoSmithKline Capital releases 2024 annual report

LONDON - GlaxoSmithKline (NYSE:GSK) Capital PLC, a subsidiary of the pharmaceutical giant GSK Group, announced today the release of its 2024 Annual Report. The document, which details the company’s financial performance and principal risks, is now accessible on the GSK Group website and has been submitted to the UK Financial Conduct Authority’s (FCA) National Storage Mechanism.

The annual report provides insights into the company’s financial health for the year ending December 31, 2024. It includes a comprehensive Directors’ responsibility statement and discusses the main risks and uncertainties that could potentially affect the company’s future operations. These disclosures are part of the company’s commitment to transparency and compliance with regulatory requirements.

Investors and interested parties can view the full text of the report by visiting the FCA’s dedicated submission portal. The company has utilized the exemption under the Disclosure and Transparency Rules, opting to make the full report available online rather than including the complete text in this announcement.

In line with regulatory practices, GlaxoSmithKline Capital has cautioned investors about forward-looking statements made in the report. These statements are subject to various risks and uncertainties that might cause actual results to differ from projections. The "Risk Factors" section of GSK’s Annual Report on Form 20-F for 2024 provides a detailed description of these potential risks.

This announcement, made by V A Whyte, Company Secretary on Tuesday, emphasizes the availability of the annual report and underscores the company’s adherence to the listing rules of the FCA. It is based on a press release statement and aims to inform stakeholders of the company’s financial status and future outlook as per the information provided by the company.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.